Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 Data collection
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of neutropenia
3.2.1.2 Growing utilization of chemotherapy
3.2.1.3 Government initiatives and support aimed at raising awareness
3.2.1.4 Rising R&D efforts expand robust drug pipeline
3.2.1.5 Increasing advancements in pharmaceutical drug delivery technology
3.2.1.6 Favorable reimbursement policies support treatment accessibility
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulations for product approvals
3.2.2.2 Adverse effects associated with the treatment
3.3 Growth potential analysis
3.4 Pipeline assessment
3.5 Reimbursement scenario
3.6 Regulatory landscape
3.7 Porter’s analysis
3.7.1 Supplier power
3.7.2 Buyer power
3.7.3 Threat of new entrants
3.7.4 Threat of substitutes
3.7.5 Industry rivalry
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018-2032 ($ Million)
5.1 Key trends
5.2 Colony-stimulating factors (CSFs)
5.3 Antibiotics
5.4 Antifungals
5.5 Antivirals
5.6 Other treatment types
Chapter 6 Market Estimates and Forecast, By Drug Type, 2018-2032 ($ Million)
6.1 Key trends
6.2 Branded
6.3 Biosimilars
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018-2032 ($ Million)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By Indication, 2018-2032 ($ Million)
8.1 Key trends
8.2 Chemotherapy-induced neutropenia
8.3 Cyclic neutropenia
8.4 Idiopathic neutropenia
8.5 Congenital neutropenia
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018-2032 ($ Million)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Amgen Inc.
11.2 BeyondSpring Inc.
11.3 Biocon Biologics Inc.
11.4 Cellerant Therapeutics
11.5 Coherus BioSciences, Inc.
11.6 CuraTeQ Biologics Pvt. Ltd.
11.7 Evive Biotech
11.8 Kyowa Kirin Co., Ltd.
11.9 Pfizer Inc.
11.10 Sandoz Inc.
11.11 Spectrum Pharmaceuticals
11.12 Teva Pharmaceutical Industries Ltd.
